US FDA "Study May Proceed" Letter for Clarity's Cu-64 SAR-bisPSMA Trial in Prostate Cancer

SYDNEY, Feb. 7, 2022 -- (Healthcare Sales & Marketing Network) -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleas... Biopharmaceuticals, Diagnostics, Oncology, FDA Clarity Pharmaceuticals, Copper-64 SAR-BisPSMA, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news